aXichem files patent application for aXivite as performance-enhancing ingredient in dietary supplements for physical training
aXichem AB (publ), (aXichem), a provider of innovative natural analogue ingredients to the nutraceutical market, announces that the company has submitted a patent application for aXivite as a performance-enhancing ingredient in dietary supplements intended for physical training. The title of the patent is "Physical performance aid" and has its background in significant effect data from above all the study described in the recently published scientific article “Effects of different phenylcapsaicin doses on resistance training performance, muscle damage, protein breakdown, metabolic response, ratings of perceived exertion and recovery: A randomized, triple-blinded, placebo-controlled, crossover trial.” which can be read in Journal of the International Society of Sports Nutrition (JISSN).
”The market for performance-enhancing products continues to grow as an increasingly large group of people train and compete at a high level and spend a lot of time on their training. According to a report from the Nutrition Business Journal, the exercise and weight loss market segment grew by amazing 22% in 2021. Given that we saw in the study, that higher doses of aXivite increase performance by approximately 10 percent in trained athletes, a patent in this application is commercially important,” says Torsten Helsing, CEO in aXichem.
About phenylcapsaicin and aXivite
aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capsaicin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.
The information was submitted, through the care of the contact person below, for publication on 25 April 2023, at 10:30 AM CET.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: torsten.helsing@axichem.se
aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutraceuticals and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Västra Hamnen Corporate Finance, www.vhcorp.se. Read more about aXichem at www.axichem.se